Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 8,144 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
59
States / cities
Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

NCT01781468
View directory record Official record
Conditions
Fatigue
Interventions
armodafinil 150 mg, Placebo, armodafinil 250 mg
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
365
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 17, 2026, 9:04 AM EDT
Active, not recruiting Not applicable Interventional

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

NCT05455606
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Best Practice, Chart Abstraction, Educational Intervention, Genomic Profile, Interview, Questionnaire Administration, Tumor Board Review
Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Phoenix, Arizona • Savannah, Georgia • Honolulu, Hawaii + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed No phase listed Observational

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

NCT01649778
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 17, 2026, 9:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

NCT03832517
View directory record Official record
Conditions
Safety
Interventions
Single intravenous doses of RC-01, Single intravenous doses of placebo, Multiple intravenous doses of RC-01, Multiple intravenous doses of placebo
Drug
Lead sponsor
Recida Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

NCT01744691
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • Greenbrae, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Long-Term, Open Label Atomoxetine Study

NCT00190684
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 18 Years
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2011 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

NCT01027949
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 17, 2026, 9:04 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 17, 2026, 9:04 AM EDT
Terminated Early Phase 1 Interventional

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT04559685
View directory record Official record
Conditions
High Grade Glioma
Interventions
SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS), MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product · Device
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

NCT00518115
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide (GSK716155) or exenatide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
158
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

NCT03371108
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 17, 2026, 9:04 AM EDT
Recruiting No phase listed Observational

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

NCT06129240
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
LIQ861
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

NCT01227668
View directory record Official record
Conditions
Irritability Associated With Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Dothan, Alabama • Phoenix, Arizona • Costa Mesa, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

NCT00551148
View directory record Official record
Conditions
Primary Insomnia
Interventions
PD 0200390, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Glendale, Arizona • Phenoix, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 17, 2026, 9:04 AM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

NCT04930289
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions
LungGuard, BAROGuard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Terminated No phase listed Observational

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

NCT04149197
View directory record Official record
Conditions
Alzheimer's Disease in Down Syndrome
Interventions
Not listed
Lead sponsor
LuMind IDSC Foundation
Other
Eligibility
25 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 17, 2026, 9:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421
View directory record Official record
Conditions
Neoplasms
Interventions
Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

NCT05545306
View directory record Official record
Conditions
Obesity, Normal Physiology, Healthy Volunteers
Interventions
+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, fasting, -50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein, -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

NCT01105858
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy, Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2,310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

NCT06588296
View directory record Official record
Conditions
Psoriatic Arthritis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
81
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

NCT00739362
View directory record Official record
Conditions
Electric Stimulation Therapy, Obesity, Weight Loss, Eating
Interventions
Transcranial Direct Current Stimulation (TDCS), Sham/no-stimulation
Device · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246
View directory record Official record
Conditions
HIV-1 Infection
Interventions
F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
34
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 17, 2026, 9:04 AM EDT